Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2011

Oct 6, 2011

30016_dirs_2011-10-06_e8d10c6e-ae15-4170-843d-c590a582cd94.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2011-10-04

Reporting Person: AYERS JONATHAN W (Director, CHAIRMAN, PRESIDENT & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-10-04 Common Stock M 20000 $12.6 Acquired 317697 Direct
2011-10-04 Common Stock S 9500 $64.2054 Disposed 308197 Direct
2011-10-04 Common Stock S 5500 $64.5939 Disposed 302697 Direct
2011-10-05 Common Stock M 20000 $12.6 Acquired 322697 Direct
2011-10-05 Common Stock S 14597 $66.1209 Disposed 308100 Direct
2011-10-05 Common Stock S 403 $66.7387 Disposed 307697 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-10-04 Non-Qualified Stock Option (right to buy) $12.60 M 20000 Disposed 2012-01-28 Common Stock (20000) Direct
2011-10-05 Non-Qualified Stock Option (right to buy) $12.6 M 20000 Disposed 2012-01-28 Common Stock (20000) Direct

Footnotes

F1: Includes 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2011.

F2: The reported sale above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.

F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $63.88 to $64.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.

F4: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.00 to $65.43, inclusive.

F5: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.66 to $66.57, inclusive.

F6: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $66.69 to $66.75, inclusive.

F7: Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.